Yazarlar (3) |
![]() |
![]() Türkiye |
![]() Kastamonu Üniversitesi, Türkiye |
Özet |
Osteoporosis is a disease characterized by low bone mass and the microarchitectural deterioration of bone tissue, leading to bone fragility and increased fracture risk [1]. Most of the therapies used for the treatment of osteoporosis inhibit bone resorption and prevent further bone loss. However, as many osteoporosis patients already lost a large amount of bone at their diagnosis, agents need agents to stimulate new bone formation [2].This approach’s drug and enhancements’ discovery goal is to identify a CaSR-antagonist, that is, rapidly absorbed (short Tmax) and fairly rapidly eliminated. Based on its overall in vitro and physicochemical properties, one of the BMSF-BENZ derivatives ((4-Bromo-7-methoxy-1-(2-methoxyethyl)-5-{[3-(methylsulfonyl) phenyl] methyl}-2-[4-(propane-2-yl) phenyl]-1H-1, 3-benzothiazole)(Figure 1) was selected because it showed a sharp PTH-release peak and good properties regarding CaSR receptor [3]. With the increasing development of |
Anahtar Kelimeler |
Makale Türü | Özgün Makale |
Makale Alt Türü | Uluslararası alan indekslerindeki dergilerde yayınlanan tam makale |
Dergi Adı | European Journal of Chemistry |
Dergi ISSN | 2153-2249 |
Dergi Tarandığı Indeksler | WorldCat, Index Copernicus |
Makale Dili | Türkçe |
Basım Tarihi | 01-2021 |
Makale Linki | www.eurjchem.com |